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Abstract 
Access to the most effective treatments is not universal and treatment coverage for the 
prevention of mother-to-child transmission (PMTCT) is still low in many countries, including 
Kenya (WHO, 2010a).  To improve uptake of PMTCT to reduce perinatal HIV transmission the 
World Health Organization (WHO) issued new treatment guidelines for use among pregnant 
HIV+ women in 2010 (WHO, 2010b). In the same year, Kenya’s National AIDS and STI 
Control Programme (NASCOP) established revised guidelines for PMTCT. Despite expanded 
treatment guidelines it is unclear if women meeting the minimum requirements for treatment and 
ARV prophylaxis during pregnancy and postpartum follow-up are receiving treatment according 
to WHO and NASCOP recommendations. This study will examine the antenatal treatment 
regimens of HIV-infected women reporting to four hospitals in Kenya for Early Infant Diagnosis 
(EID) of HIV services. It will assess the extent to which PMTCT regimens of these HIV+ 
mothers reflect the revised PMTCT treatment guidelines, and if children born to mothers on less 
efficacious treatment regimes have higher HIV positivity rates. 
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CHAPTER 1 
Introduction 
Globally, an estimated 34 million people are living with HIV/AIDS with 7,000 new 
infections occurring each day (UNAIDS, 2011a). Sub-Saharan Africa continues to be 
disproportionately affected by the virus as the region is comprised of 22.9 million individuals 
living with HIV. Roughly 16.8 million women and 3.4 million children are presently living with 
HIV worldwide (UNAIDS, 2011a). Kenya, with a total population of around 40.5 million (World 
Bank, 2010), has an estimated 1.6 million individuals living with HIV/AIDS (NACC, 2011). 
Kenya has the third largest population of individuals living with HIV/AIDS in sub-Saharan 
Africa. As of December 2011, around 6.2% of Kenyans between the ages of 15-49 are HIV-
positive (NACC, 2011). HIV prevalence in Kenya peaked at around 10.5% in 1995-1996 
(NACC, 2011). Women are disproportionately affected by HIV with 8% of adult Kenyan women 
infected compared to 4.3% of men. Approximately fifty-nine percent of all HIV infections in 
Kenya occur among women (NACC, 2011). As of 2009 there were 184,052 HIV-infected infants 
and children living in Kenya (NACC, 2010) with 12,894 new infections occurring among infants 
and children in 2011 (NACC, 2011) down 30% from 2010. 
Increased financial and technical support from global health agencies and NGOs like the 
President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, 
Tuberculosis, and Malaria, have helped increase the proportion of eligible HIV+ people 
receiving ART from 7% in 2003 (WHO, 2006) to 47% in 2010 (UNAIDS, 2011b). Reducing the 
number of infants and children infected with HIV has been an imperative component of the 
global public health response to the HIV epidemic. Use of prophylactic ARVs during pregnancy 
dramatically reduces the risk of HIV-transmission to infants during pregnancy, labor and 
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delivery, or during breastfeeding from 15-45% (without ART) (WHO, 2012a) to as low as 1-2% 
(with ART, safe delivery, and replacement feeding) (Townsend et al., 2008). Thus, targeted 
prevention efforts among pregnant women in resource-poor settings are imperative to reduce 
HIV prevalence among future generations. 
To establish global standards for HIV prevention and treatment, the World Health 
Organization (WHO) outlines treatment guidelines specific to the prevention of mother-to-child 
transmission (PMTCT) through antiretroviral therapy. Individual countries are encouraged to 
adapt WHO guidelines and release country-specific instructions based on their resources. In 
2010 the WHO released an updated and more rigorous version of the PMTCT guidelines and 
Kenya’s National AIDS and STI Control Programme (NASCOP) published National PMTCT 
guidelines shortly thereafter (outlined in sections 2.4 and 2.5). 
However, access to the most effective treatments is not universal in Kenya. Despite 
expanded treatment guidelines, it is unclear if women meeting the minimum requirements for 
treatment and ARV prophylaxis during pregnancy and postpartum follow up receive treatment 
according to the revised global and national guidelines. Even in settings where ARVs are 
available, several clinical and patient-related barriers negatively impact the appropriate 
implementation of WHO and/or NASCOP PMTCT guidelines. Clinical barriers include 
inefficacious regimes and drug resistance, lack of service integration, weak healthcare 
infrastructure, and deficiencies in clinical training. Patient barriers include late or non-attendance 
at antenatal clinics, stigma, financial concerns, male and familial involvement, and loss to 
follow-up.  
This study will examine the antenatal treatment regimens of HIV-infected women 
reporting to four government hospitals for Early Infant Diagnosis of HIV (EID) clinics in Kenya 
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from March 2010 to June 2012. The study aims to assess compliance with the 2010 revised 
PMTCT guidelines promoted by the WHO and NASCOP, and to assess if children born to 
mothers on less efficacious treatment regimes have higher HIV positivity rates. 
CHAPTER 2 
Review of Literature 
2.1. Seminal research in prevention of mother-to-child transmission (PMTCT) of HIV 
infection 
 Antiretroviral therapy drug options were first proven effective in reducing mother-to-
child HIV transmission in 1994 by the Pediatric AIDS Clinical Trials Group (PACTG 076) 
(Connor et al., 1994). An analyses by Connor and colleagues of 363 infants in the United States 
and France found that zidovudine (AZT) given during pregnancy and labor to mothers and 
postpartum to newborns, reduced MTCT at 18 months to 8.3% compared with a 25.5% 
transmission rate in the placebo group. However, the AZT regimen administered in the PACTG 
076 trial was both complex and costly as antenatal dosing began at 14 weeks gestation. 
Following the results of the PACTG 076 trial it was evident that more cost effective ART would 
be necessary in order to reduce MTCT in resource-poor settings. Subsequent research (Shaffer et 
al, 1999; Dabis et al, 1999) attempted to decrease costs by providing later antenatal treatment 
initiation (i.e. 28 weeks or later) of AZT in mothers or in some cases eliminating postpartum 
ART prophylaxis in mothers or infants. Efficacy in successive research with AZT-only treatment 
was lower than that of the initial long-course PACTG076 (Connor et al., 1994, Lallemant et al., 
2000), but still found to be better than rates among placebo groups (Dabis et al, 1999, Shaffer et 
al, 1999). 
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 Previous research has demonstrated that earlier initiation of antiretroviral therapy during 
the antenatal period is more efficacious as is administration of ARVs during all three time frames 
of pregnancy (i.e. antenatal, intrapartum, and postpartum) (Lallemant et al., 2000, PETRA, 
2002). PMTCT regimens with antenatal prophylaxis are preferred, however, many women do not 
present for PMTCT until delivery. As such, late course and postpartum regimens would also 
need to be considered. Lallemant and colleagues (2000) established that AZT prophylaxis started 
at 28 weeks gestation (1.6%) was more effective than prophylaxis started at 36 weeks gestation 
(5.1%) in preventing in-utero infections. However, many women do not present to the formal 
health sector until they are in labor. Accordingly, antiretroviral therapy administered only during 
the delivery and postpartum periods has also proven effective at reducing MTCT rates (PETRA, 
2002), but treatment administered at delivery alone without postpartum therapy has not proven 
effective (PETRA, 2002).  
Following PACTG 076 (Connor et al., 1994), several clinical trials successfully reduced 
MTCT rates utilizing shortened-course antenatal AZT regimes versus placebo (Dabis et al., 
1999, Lallemant et al., 2000, Shaffer et al., 1999). In the early 2000’s clinical trials began 
utilizing combination ART drug therapies, particularly regimen variations of nevirapine, 
zidovudine, and lamivudine, for use in PMTCT (Dabis et al., 2005, Lallemant et al., 2004, 
Moodley et al., 2003, PETRA, 2002).  Nevirapine, a non-nucleoside reverse transcriptase 
inhibitor (NNRTI), became particularly popular for use in resource-constrained settings due to its 
low cost, quick absorption, and long-lasting biological half-life (i.e. the time it takes for half the 
drug to be eliminated from the bloodstream) (WHO, 2000). In 1999, preliminary results of the 
HIVNET 012 began to shift focus of PMTCT therapy to regimens consisting of single-dose 
nevirapine administered at delivery and postpartum (Guay et al., 1999, Jackson et al., 2003). 
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Rates of MTCT at 18 months among Ugandan infants in the HIVNET 012 trial were 15.7% 
among mothers receiving intrapartum sd-NVP and infants receiving sd-NVP after birth. MTCT 
was 25.8% among those receiving intrapartum AZT with 1 week of AZT follow-up for the 
infant. Results of the HIVNET 012 trial were controversial prior to the final results being 
published (Jackson et al., 2003, Jackson & Fleming, 2005, Swingle, 2001) due to concerns about 
alterations made in the trial methodology and study procedures. Ultimately the US Institute of 
Medicine found the HIVNET 012 results to be sound (Brierly, 2005) and thus sd-NVP became 
the regime of choice in the developing world. In 2000, Boehringer Ingelheim, the manufacturer 
of nevirapine began distributing free nevirapine to 59 developing countries making it both simple 
and affordable (Boehringer Ingelheim, 2007) and thus expanding PMTCT programs in the 
developing world. 
Subsequent research found that single-dose nevirapine was more effective at reducing 
MTCT among breastfeeding infants in a South African clinical trial in which mothers were not 
administered prophylactic antiretroviral therapy. Breastfed infants receiving sd-NVP had a 
12.2% transmission rate whereas infants given 6 weeks of AZT had a 19.6% MTCT rate (p  = 
0.03) (Gray et al., 2005). This distinction was not observed among formula-fed infants. Another 
nevirapine trial with mothers and infants in Uganda, Ethiopia, and India (SWEN Study Team, 
2008) compared MTCT rate after mothers received sd-NVP at delivery and infants received 
either sd-NVP at birth or NVP daily for 6 weeks post birth. Transmission rates were 5.3% in 
infants receiving only sd-NVP and 2.5% (p = 0.009) in infants receiving extended nevirapine. At 
6 month follow-up MTCT in infants receiving only sd-NVP was 9.0% and 6.9% (p = 0.16) in 
infants receiving extended nevirapine. Moreover, infant mortality was significantly lower among 
the infants who received extended nevirapine (SWEN Study Team, 2008). 
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The SAINT trial (Moodley et al., 2003) observed comparable rates of MTCT at 8 weeks 
when comparing sd-NVP (12.3%) and combination therapy of AZT and 3TC (9.3%) 
administered at delivery and postpartum for both mother and infant. Research in Thailand 
(Lallemant et al., 2004) examined antenatal AZT along with either intrapartum AZT or sd-NVP 
and postpartum AZT with or without sd-NVP and found higher transmission rates among those 
that received AZT alone (6.3%) compared to AZT and sd-NVP (1.1%). MTCT transmission 
rates in participants receiving AZT and sd-NVP were similar to those found among infants in the 
United Kingdom and Ireland (Townsend et al., 2008). However, there was not a significant 
difference in MTCT rates among infants that received sd-NVP (2.0%) and those that did not 
(2.8%) (Lallemant et al., 2004).  
Soon after PMTCT programs began to focus on sd-NVP, concerns began to arise about 
burgeoning resistance to nevirapine among HIV+ women and their infants. Due to nevirapine’s 
long half life and low genetic barrier to resistance, most women and infants using sd-NVP will 
experience some resistance to the drug, if only temporarily (Arrivé et al., 2007, Cressey et al., 
2005). Still, resistance is of paramount concern among women of child-bearing age as ARV 
resistance to short course prophylaxis regimens can reduce the efficacy of PMTCT and limit 
drug therapy options for future treatment or pregnancies. Viral resistance to nevirapine, a non-
nucleoside reverse transcriptase inhibitor (NNRTI), leads to resistance to other NNRTI drugs 
within the same drug class eliminating lower-cost options in the event of treatment failure. A 
meta-analysis conducted by Arrivé and colleagues (2007) found nevirapine resistance of 35.7% 
(n=950, CI: 23.0 – 50.6) among participants in 10 studies using single-dose NVP. Resistance of 
only 4.5% (n=223, CI: 2.1-9.4) was observed among 3 studies utilizing combination ARV 
therapy. Nevirapine resistance in infants was 52.6% (n=201, CI: 37.7 – 67.0) among infants in 
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seven studies with exposure to sd-NVP drug regimens compared with 16.5% (n=138, CI: 8.9 – 
28.3) among infants in eight studies with exposure to combination ARV therapy (Arrivé et al., 
2007).  
Follow-up analysis of the Indian arm in the SWEN study (SWEN Study Team, 2008) 
also documented substantial rates of resistance among nevirapine exposed infants (Moorthy et 
al., 2009). Results of the resistance analysis revealed higher rates of drug-resistant nevirapine 
mutations among infants diagnosed with HIV in the first six weeks of life and randomized to the 
six-week extended nevirapine study arm (92%) versus the sd-NVP arm (38%) (p = 0.002). This 
observation was also found among infants infected through breastfeeding and randomized to the 
six-week extended nevirapine arm (100%) versus the sd-NVP arm (27%) (p = 0.008). Similarly, 
these alarming rates of resistance were also observed in an analysis of the Ugandan arm of the 
SWEN trial (Church et al., 2008).  
While, sd-NVP is inexpensive and easy to administer, questions about increased risk of 
developing resistance encouraged WHO to remove sd-NVP from PMTCT treatment 
recommendations (WHO, 2010b). Triple antiretroviral prophylaxis or HAART options are now 
advised based on research indicating lower MTCT rates among women receiving triple ARV 
therapy for PMTCT (Kesho Boro Study Group, 2011, Kilewo et al., 2009, Shapiro, et al., 2010, 
Thomas et al., 2011). New research utilizing triple ARV therapy has also found reductions in 
MTCT rates, comparable to those in western countries (Townsend et al., 2008), even with later 
initiation of antenatal prophylaxis. Observational studies of women receiving antenatal and 
postpartum ZDV/3TC/NVP initiated at 34 weeks gestation found cumulative transmission rates 
of 5% at 6 months (Kilewo et al., 2009, Thomas et al., 2011). Randomized trials comparing triple 
antiretroviral therapies have had promising results. The Mma Bana study from Botswana 
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compared two triple ARV therapy options, both administered at 26 weeks through 6 months 
postpartum. Women received either ZDV/3TC/ABC or ZDV/3TC/LPV/r. For women receiving 
ZDV/3TC/ABC MTCT at 6 months was 2.1% and or 0.4% among the ZDV/3TC/LPV/r arm (p = 
0.53) (Shapiro et al., 2010). The Kesho Bora study compared women receiving triple ARV 
therapy with ZDV/3TC/LPV/r to women receiving only dual therapy with ZDV + sdNVP 
beginning at 28 weeks gestation. Women in the triple ARV group also received postpartum 
therapy for 6 months whereas women in the dual therapy arm received ZDV/3TC for 1 week. 
Transmission rates at 12 months were 5.4% among the infants in the triple ARV arm compared 
to 9.5% in the dual therapy arm (p = 0.029) (Kesho Boro Study Group, 2011). 
2.2. Progression of antenatal care in Kenya: PMTCT, early infant diagnosis (EID), and 
infant feeding practices 
Pregnant women in Kenya generally have higher rates of uptake in prenatal services than 
women in comparable sub-Saharan African countries (World Bank, 2010). Kenya’s PMTCT 
program, originally initiated on a pilot basis beginning in 2000, has expanded to integrate 
PMTCT services into existing maternal and child healthcare facilities. By the end of 2009, 
approximately 50% of Kenyan health facilities offered PMTCT services (NACC, 2010), and an 
estimated 58,591 HIV+ women received PMTCT treatment services that year (NASCOP, 2011). 
In 2010, 37,204 HIV+ pregnant women in Kenya received antiretroviral therapy for preventing 
mother-to-child transmission. Approximately one-third of those enrolled in PMTCT receive an 
inadequate or inferior ARV regimen, and according to WHO, a projected 75 – 100,000 Kenyan 
women are in need of efficacious treatment (NACC, 2010, WHO, 2010a).   
 HIV testing, counseling, and referral services as well as access to antiretroviral therapy 
are the foundation of PMTCT. HIV testing and counseling should be provided as early as 
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possible in the pregnancy, so that women identified as positive can begin their PMTCT ARV 
regimen early enough to benefit themselves and their infant (WHO, 2007).  The 2007 WHO 
recommendations (Guidance on provider-initiated HIV testing and counseling in health 
facilities) advise an opt-out approach to HIV testing, in an effort to routinize HIV testing among 
pregnant women and maximize the number of pregnant women screened. In 2010, 83% of 
pregnant women in Kenya were tested for HIV during their pregnancy (WHO, 2010a). Women 
that test negative should be re-tested again later in pregnancy and educated about how to avoid 
infection during the antenatal and postpartum periods. 
 Pregnant women identified as HIV+ are then encouraged to participate in the PMTCT 
program. PMTCT protocols that consider the woman’s CD4 cell count (measure of her immune 
system strength), presence of any clinical symptoms, gestational stage, and treatment history 
inform the best ARV strategy PMTCT. Women with lower CD4 counts and those presenting at 
advanced gestational age need to start ART or ARV prophylaxis without delay during 
pregnancy, labor and delivery, and during the postpartum period to prevent MTCT. 
Antiretroviral (ARV) prophylaxis is most successful at PMTCT when given during pregnancy, 
labor, and through the duration of breastfeeding; it can also be effective when started at the time 
of labor and when the infant is given ARV treatment after birth (WHO, 2010b). 
 HIV-infected mothers enrolled in PMTCT services are also counseled on infant follow-
up care, including infant feeding practices. Formula replacement feeding is the only way to 
completely eradicate mother-to-child HIV transmission via breastfeeding. In resource-poor 
settings formula feeding isn’t safe, affordable, feasible, or in many cases socially acceptable. 
Consequently, research has focused on determining the safest methods of breastfeeding for 
infants with HIV-infected mothers. Comparisons of exclusive breastfeeding and mixed-feeding 
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(e.g. combination of breastfeeding and formula feeding) have found lower rates of transmission 
among women who breastfeed exclusively (Iliff et al., 2005; Kuhn et al., 2007, Becquet et al., 
2008). Kenya’s PMTCT guidelines also outline best practices for infant feeding noting that 
replacement feeding is only advised when it is acceptable, feasible, affordable, sustainable, and 
safe for both mother and infant. 
 Early infant diagnosis (EID) was introduced in Kenya in 2006 as a subprogram of 
PMTCT with the aim of earlier detection and treatment initiation among HIV-infected infants. 
EID programs have grown rapidly from 434 health facilities serving 24,615 infants in 2007 to 
approximately 1,500 health facilities serving 55,604 infants in 2010 (NACC, 2011). As of 2009 
approximately 61% of eligible children were tested for HIV (NACC, 2010). EID refers to 
diagnosing HIV in infants before 18 months of age and is extremely important due to rapid 
disease progression and a high mortality rate of HIV-infected infants. In the absence of 
intervention, one fourth of children with HIV die before their first birthday and the majority will 
die before age five. ARV treatment and co-trimoxazole prophylaxis have helped to substantially 
reduce infant mortality due to HIV infection. As of 2009, around 24.2% of eligible children and 
infants in Kenya are receiving HAART (NACC, 2010). 
EID of HIV requires more expensive and sophisticated testing strategies. Because HIV 
antibodies are passed from mother to infant in utero and can persist in the infant for up to 18 
months post-delivery (WHO, 2007), the HIV status of infants younger than 18 months cannot be 
determined with standard serologic or antibody tests. Rather, more costly virologic testing using 
HIV-DNA polymerase chain reaction (PCR) of dried blood spots is the gold standard for EID 
(WHO, 2010d), and has been identified as being structurally feasible in Kenya (Khamadi et al., 
2008). Diagnosis of HIV in a child under 18 months is based on a positive HIV DNA PCR test, 
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ideally provided by 6 weeks of age. Infants can become infected with HIV during pregnancy, 
labor, or via breastfeeding during the postpartum period. Due to their undeveloped immune 
systems infants have quicker disease progression making the need for timely testing of 
paramount importance (Shearer et al., 1997, Rouet et al., 2003). Infections suspected during 
labor and delivery or postpartum will take longer to detect. In Kenya, EID guidelines indicate re-
testing at 9 months and again at 18 months to rule out MTCT of HIV.  
2.3. World Health Organization PMTCT Treatment Guidelines 
 In 2001, the WHO published the first recommendations for ART treatment with 
nevirapine-based regimens in pregnant women (WHO, 2001). Revisions were made to the 
guidelines in 2003, 2006, and most recently in 2010. In addition to proposing earlier ART 
initiation for pregnant women, the changes suggest routine and accessible monitoring of CD4 
cell count, an increased number of efficacious treatment options, and recommendations to 
discontinue use of drug regimes previously found to be less-tolerated among HIV-infected 
patients (WHO, 2010b, WHO, 2010c). 
New global guidelines recommending earlier initiation and extended prophylaxis with 
HAART will significantly increase the number of individuals in need of adequate antiretroviral 
therapy. Stanecki and colleagues (2010) found that the number of individuals in low and middle 
income countries eligible for ART under the new guidelines would increase to 14.6 million 
under the 2010 guidelines compared to 10.1 million under the 2006 guidelines (Stanecki et al., 
2010). Sub-Saharan Africa sees the majority of ART burden with an estimated 10.6 million 
individuals eligible for ART under the new guidelines compared to only 7.4 million under the 
previous ones. In Kenya alone, the new guidelines increase the numbers eligible for ART from 
520,000 to around 750,000 individuals (Stanecki et al., 2010).  
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WHO guidelines specific to pregnant women and infants were also updated in 2010 
based on evidence indicating that earlier initiation of HAART prophylaxis during pregnancy and 
extended postpartum treatment during the breastfeeding period could effectively reduce global 
MTCT risk to less than 5% (WHO, 2010b). Building upon the public health approach to PMTCT 
first introduced in the 2006 guidelines, the 2010 guidelines reiterate the importance of lifelong 
ART to pregnant women that meet treatment criterion. Additionally, the 2010 guidelines 
expanded the recommendations for treatment prophylaxis to include treatment both in early 
pregnancy and during breastfeeding rather than focusing strictly on the third trimester of 
pregnancy. 
The new guidelines emphasize two treatment approaches for HIV-infected pregnant 
women: lifelong ART and ARV prophylaxis. Lifelong ART applies to HIV-infected women 
currently eligible for treatment on the basis of their own health as indicated by CD4 less than 350 
or clinical symptoms. Pregnant women in need of lifelong HAART should be prescribed 
treatment regimes that are both safe and effective in PMTCT as the clinician should anticipate 
future pregnancies as well. ARV prophylaxis pertains to the temporary initiation of HAART 
during pregnancy, delivery, and breastfeeding when a pregnant woman is not in need of 
treatment based on her CD4 or clinical symptoms. Medications are administered until risk of 
MTCT is no longer present which is after the conclusion of breastfeeding post labor. Prophylaxis 
should be initiated as early 14 weeks of gestation or as soon as possible thereafter if the woman 
presents to care later in her pregnancy or during labor and delivery. 
Under updated recommendations, women with a CD4 count of ≤350 cells/mm
3
 should be 
started on ART regardless of clinical symptoms. Furthermore, women who present with 
advanced clinical symptoms as defined in WHO clinical stage 3 or 4 (Insert Figure 1 about here) 
13 
 
should start ART regardless of the CD4 count. For women who present in WHO clinical stage 1 
or 2, CD4 testing is required to determine when to start ARV treatment or prophylaxis for 
PMTCT. 
 WHO (2010c) guidelines suggest two HAART treatment and prophylaxis options for 
HIV-infected pregnant women as found in Figure 2 (Insert Figure 2 about here). Option A 
includes twice daily AZT starting as early as 14 weeks gestation during the antepartum period, 
followed by single-dose NVP at commencement of labor, and concluded with AZT/3TC 
postpartum. Infants born to an HIV-infected mother receiving treatment via Option A should also 
receive daily NVP until after breastfeeding has ended. Option B includes triple ARV prophylaxis 
starting as early as 14 weeks gestation and continued until delivery or until 1 week after all infant 
exposure to breast milk has ended in the postpartum period. Similarly infants should receive 
daily NVP or twice daily AZT from birth until 4 to 6 weeks of age. In addition a WHO 
programmatic update released in April 2012 outlined Option B+ which suggests that triple ARVs 
be continued for life even among women started on prophylaxis regimes during pregnancy. 
WHO suggested this update in an effort to simplify regimes, reduce further sexual transmission 
of HIV, deter discontinuing and re-starting ARVs, and to offer further reduction of mother-to-
child transmission if the mother becomes pregnant again. 
2.4. Kenyan Ministry of Health, National AIDS and STI Control Programme PMTCT 
Treatment Guidelines 
 As of 2011, over half of women receiving PMTCT are treated under Option A (60%), 
however, the Kenyan Ministry of Health has agreed to begin transitioning to Option B+. By 
December 2012, the Ministry of Health plans to have 50% of pregnant women treated under 
Option B+ (Médecins Sans Frontières, 2012, Bachman and Phelps, 2012). Transitioning to 
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Option B+ would reduce the number of mother-to-child infections as lifelong ART would mean 
mothers would already be on treatment at the onset of future pregnancies. Kenya’s commitment 
to update treatment guidelines to include Option B+ has been documented by global health 
organizations such as Médecins Sans Frontières/Doctors Without Borders, USAID and PEPFAR 
(2012). However, a programmatic update or addendum has not been issued by the Kenyan 
Ministry of Health. 
The WHO (2009) suggests the adaptation of treatment guidelines based on six key 
principles to meet country-specific conditions as implementation of the guidelines may vary 
based on resources and disease burden. Guiding principles for adaptation: (1) maintaining 
current progress towards program objectives devoid of interrupting the care of individuals at 
highest risk, (2) seek to guarantee that clinically eligible individuals are able to enter treatment 
services, (3) maintain high standards for the quality of care, (4) make certain that access to 
treatment services is fair and just, (5) choose interventions which maximize public health impact 
with the most advantageous use of human and fiscal resources, and (6) recognize the enduring 
consequences and have a sustainability plan in place (WHO, 2009). In addition, countries are 
expected to adopt forward-looking interventions that strengthen health systems and take into 
consideration the perspectives of people living with HIV/AIDS. Countries are strongly 
encouraged to have phase-based plans in place that will eventually move the country towards full 
implementation of the guidelines. After the World Health Organization released updated 
treatment guidelines in 2010, Kenya’s National AIDS and STI Control Programme followed suit 
releasing, Guidelines For Prevention of Mother-Child Transmission of HIV/AIDS in Kenya 
(Kenya Ministry of Health, 2010). 
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 Drawing on the WHO guidelines, Kenya mirrored recommendations regarding when to 
start lifelong ART. However, recommendations for ARV PMTCT prophylaxis differed slightly 
from the WHO guidelines. Kenya’s guidelines mirror WHO Option A. Women presenting for 
antenatal care are advised to start ARV therapy as early as 28 weeks gestation, compared to the 
WHO recommendation of 14 weeks gestation. Recommended regimens for WHO Option A and 
NASCOP are the same with AZT suggestion during the antepartum period, following by 
intrapartum sd-NVP and a seven day course of AZT/3TC administered postpartum. NASCOP 
does advise triple ARV prophylaxis, in accordance with WHO Option B, when feasible, a 
revision from the single-dose nevirapine regimes that were utilized under earlier guidelines. 
Recommended regimes for triple ARV prophylaxis also differed slightly between WHO and 
NASCOP recommendations. 
 Falling in line with WHO recommendations, NASCOP also updated clinical guidelines 
for PMTCT treatment initiation. NASCOP also recommends that women with a CD4 count of 
≤350 cells/mm
3
 should be started on ARVs regardless of clinical symptoms. In resource-limited 
areas where CD4 testing is not feasible, women can be started on ART in the presence of clinical 
symptoms at WHO stage 3 or 4 (Insert Figure 1 about here). When the CD4 count is >250 and as 
resources allow, a protease inhibitor-based regimen utilizing lopinavir/ritonavir (LPV/r) is 
recommended over NRTI or NNRTI-based regimens. Administration of ARV prophylaxis varies 
and is dependent upon what stage of pregnancy the infected mother is in when she reports for 
antenatal visits. 
2.5. Barriers, feasibility, and implications of PMTCT World Health Organization PMTCT 
Treatment Guidelines 
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Although the latest treatment guidelines from both WHO and NASCOP expand the 
number of individuals currently in need of HIV treatment they do not necessarily provide easy 
paths to comprehensive implementation. Furthermore, barriers to antenatal care and uptake in 
PMTCT and EID programs make it difficult to implement appropriate access among all 
individuals currently in need of treatment. Research has identified clinical and patient-related 
barriers to uptake and implementation of PMTCT guidelines.  
2.5.1. Clinical barriers 
Inefficacious regimes and drug resistance Single-dose nevirapine was long-considered 
the PMTCT drug of choice as it was safe, tolerable, and inexpensive. Research now shows 
poorer outcomes for mothers on sd-NVP regimes compared with those on triple-ARV therapy. A 
study conducted in Mombasa found that the MTCT at 14-16 weeks in a sample of 127 babies 
was 18.1%, similar to the transmission rate of 21.7% at 14 weeks post delivery and prior to the 
availability of NVP (Quaghebeur, et al., 2004). However, rates of transmission on sd-NVP 
regimes have varied. A study conducted in South Africa found a lower transmission rate of 9.9% 
among 294 mothers who receive sd-NVP administered between two and twenty-four hours prior 
to delivery and infants within 72 hours after birth (Colvin, et al., 2007). 
Emerging resistance to NNRTI drugs, such as nevirapine, has been a primary concern in 
evolving treatment guidelines. According to Kenya’s National AIDS Control Council, roughly 
33% of HIV-infected pregnant women were treated with nevirapine only during antenatal care 
and follow-up as of 2009 (NACC, 2010). Research conducted by Delva and colleagues (2010) in 
Mombasa and the Kwale districts of Coast Province Kenya found that women in most Kenyan 
antenatal facilities were receiving an ARV regime of sd-NVP only (Delva et al. 2010). 
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Research conducted in Busia district of Kenya assessed the treatment regimes of 1668 
pregnant women and categorized them according to their ARV regimen’s adherence to the 2006 
WHO guidelines (Azcoaga-Lorenzo et al., 2011). Regimes were separated into three categories: 
complete protocol, partial protocol, and no protocol. Based on these categories, the HIV status of 
the infants was examined after birth. From this sample, final HIV status post breastfeeding was 
obtained for 309 infants (HIV+, n=49; HIV-, n=260). Infants were 4.6 times more likely to be 
HIV+ if mother and infant received treatment according to partial protocols, and 43 times more 
likely to be HIV+ if mother and infant received no pharmaceutical intervention at all.  
 Lack of service integration Numerous studies have included concerns about lack of 
service integration among the entire spectrum of family planning, antenatal care and follow-up. 
For example, studies have noted that many clinics often separate antenatal care and PMTCT. 
Some patients fear they will be seen in the waiting room with other patients that are known to be 
HIV-infected (Azcoaga-Lorenzo et al., 2011, Otieno, et al., 2010). Therefore, it would be 
advantageous to patients to provide PMTCT in the same clinical setting as antenatal care so that 
women are not publicly identified as being HIV-infected. On a similar note, more tightly 
integrating early infant diagnosis into antenatal care could strengthen infant testing, treatment, 
and uptake in EID.  
Weak healthcare infrastructure Research has demonstrated that Kenya has yet to fully 
implement prior versions of WHO and NASCOP guidelines even before the release of the 2010 
guidelines (Azcoaga-Lorenzo et al., 2011, Delva, et al., 2010). In order for proper 
implementation of the newest treatment guidelines clinicians must have access to all of the 
recommended resources. The newest version of the guidelines relies heavily on the availability 
of CD4 cell count assessment which has limited availability in many clinical settings (Azcoaga-
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Lorenzo et al., 2011). In addition, health care facilities are frequently short staffed and health 
care workers are overburdened. As a result, many patients experience long wait times when 
trying to access antenatal care (Anand et al., 2009, Bwirire et al., 2008). These issues have led 
some patients to report a lack of faith in their health care services (Otieno et al., 2010) which 
contributes to lack of continued care.  
Deficiencies in clinical training Kenya currently has only 0.1 physicians for every 1,000 
inhabitants compared to 7.9 physicians for every 1,000 inhabitants in European countries (World 
Bank, 2010). Kenya, like many countries in the developing world has experienced medical 
“brain drain,” with many Kenyan-trained physicians leaving to practice medicine in Western 
countries. Physicians and medical personnel often report feeling overburdened, overworked, and 
ill-prepared in light of Kenya’s health situation (NACC, 2011). Inadequate training of service 
providers and lack of understanding of PMTCT and EID referrals has created difficulty in some 
patients reporting for care (Hassan et al., 2012).   
As a result of training deficits, patients have also encountered problems with clinical staff 
bias in regards to their chosen feeding practices for infants. Women have reported that overly 
enthusiastic clinical staff can be pushy in encouraging patients to partake in artificial feeding 
even though the social environment is not conducive to artificial feeding. Bottle-feeding is not 
feasible for most women as it is both expensive and would disclose their status to others 
(Bwirire, et al., 2008). Moreover, HIV testing procedures for mothers reporting for antenatal care 
have also been a source of losing patients to follow up. Opt-out testing is recommended by WHO 
(2007) due to higher test acceptance and the ability to identify more infections. While opt-out 
testing provides patients with the option to decline testing, some patients report feeling forced to 
consent to HIV testing (Bwirire et al., 2008, Ujiji et al., 2011). Patients have admitted to test 
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acceptance due to pressure from overzealous staff.  Others have cited pressure to consent for 
testing due to worries that testing was somehow connected to their ability to access antenatal 
care services in the future.  
2.5.2 Patient-related barriers 
 Late or no antenatal clinic attendance Patients engaging in HIV care prior to developing 
the clinical symptoms of HIV disease experience better health outcomes. Likewise, HIV-infected 
pregnant women reporting for antenatal care and PMTCT treatment earlier and more often in 
pregnancy will also have the best health outcomes. Currently, the 2010 NASCOP PMTCT 
guidelines recommend women complete a minimum of four antenatal clinic visits. According to 
NASCOP guidelines ARV prophylaxis should be initiated from 28 weeks gestation or as soon as 
possible thereafter. WHO guidelines suggest treatment initiation as early as 14 weeks gestation. 
 Using data collected from 25,364 pregnant women at antenatal clinics in Coast Province, 
Kenya, Delva and colleagues (2010) found that only 13.6% of urban women and 8.8% of rural 
women attended four or more antenatal visits. Furthermore, 52.2% of rural women and 49.2% of 
urban women attended antenatal clinic visits only once, and 30% of all women in the study had 
their first ANC visit after 28 weeks gestation. Even with extensive community-based 
involvement with active participation in the promotion of ANC services, in one study only 10% 
of women completed the four-visit schedule (Delva, et al., 2010). Evidence suggests that 
initiating ART PMTCT prophylaxis starting on the very first ANC visit could motivate patients 
to engage in care and follow-up in care. 
Another factor contributing to lackluster antenatal clinic care attendance is home 
delivery. The National AIDS Control Council of Kenya reports that as of 2009 only 44 percent 
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of pregnant women give birth at a health facility. Mothers who deliver at home are also more 
likely to have poorer adherence to ARV treatment (Azcoaga-Lorenzo et al., 2011).  
Stigma Stigma, denial, and fear of societal rejection continue to be some of the greatest 
barriers to accessing care for many HIV+ individuals. Surveys conducted among 116 Kenyan 
women post PMTCT care found that stigma was cited by over 78% of participants as a barrier to 
accessing care (Otieno et al., 2010). Stigma is often the key barrier in disclosure of HIV status to 
family and friends (Azcoaga-Lorenzo et al., 2011, Kulzer et al., 2012). Involving religious 
leaders, healers, and other individuals with obvious influence on the community in HIV outreach 
and education is one way to reduce this stigma (Bwirire, et al., 2008). 
 Patient financial concerns Kenya’s HIV prevalence is highest among the top wealth 
quintile (7.2%) and lowest among Kenya’s lowest wealth quintile (4.6%) (NACC, 2011). User 
fees for ANC services were removed in 2007. However, many women still face financial and 
transportation issues which regularly hinder timely and consistent presentation to ANC visits and 
EID follow up (Bwirire et al, 2008, Delva et al., 2010, Hassan et al., 2012, Otieno et al., 2010). 
Women in rural areas, in particular, report struggling with transportation issues as a result of 
having to travel to a more central or urbanized setting to access clinical services.   
Male and familial involvement Several studies mention lack of familial involvement, 
particularly that of the father of the baby as a barrier to uptake in PMTCT and ANC follow up 
(Bwirire et al., 2008, Delva et al., 2010, Kulzer et al., 2012, Otieno, et al., 2010). Male partners 
wield significant influence in regards to their female partner’s infant feeding choices and 
adherence to PMTCT-prescribed antiretrovirals (Otieno et al., 2010). Yet it is uncommon for 
men to be present with mothers during antenatal visits and delivery. As such there is a missed 
opportunity to offer HIV testing to both partners. Furthermore, engaging entire familial units in 
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care can help to combat stigma and promote understanding.  A study conducted in the Nyanza 
province of Kenya (Kulzer et al., 2012) utilized a family model of care to link HIV+ index 
patients to their other family members at risk. The family model of care is used to identify and 
offer care to all of a patient’s HIV-infected family members as well as present education that will 
prevent new infections among family members that are not HIV-infected. Among 285 HIV+ 
index patients there were 725 (2.5 per index patient) family members identified as at risk for 
HIV. Of the 725 at-risk patients, 62% (n=452; 1.6 per index patient) were tested for HIV and 
39% (n=175) were found to be HIV+. 
Disclosure, particularly to male partners, for many women can be serious and sometimes 
even violent (Bwirire et al., 2008, Kulzer et al., 2012, Otieno et al., 2010). However, disclosure 
is crucial and can facilitate the partner’s awareness about their need to test. Women who 
voluntarily choose not to access HIV care are more likely to report having a male partner that has 
a negative attitude to HIV care or is not aware of their diagnosis. Consequently clinics are 
beginning to integrate clinical staff that can counsel patients in regards to disclosure (Kulzer et 
al., 2012). In addition, clinics are being encouraged to adopt a more family oriented approach to 
care which will ultimately results in reducing familial stigma and increasing HIV testing among 
partners and families. 
 Lost to follow up Maintaining high retention rates in PMTCT is the only way to ensure 
prevention of mother-to-child transmission is taking place. Maternal factors (e.g. younger 
maternal age, lower education attainment, location, etc.) have been associated with failure to 
follow-up with PMTCT and EID care (Azcoaga-Lorenzo et al., 2011, Hassan et al., 2012, Otieno 
et al., 2010). Older women have been found to have their first antenatal visit earlier and follow 
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up more frequently during pregnancy than younger mothers (Delva et al., 2010). Rural women 
were also more likely to report for antenatal care earlier in their pregnancy.  
Some mothers express discomfort that PMTCT is too infant-focused and express 
dissatisfaction that not enough emphasis is put on the mother herself. Of particular concern was 
unavailability of ART when a mother believed herself to be ill enough to be offered PMTCT 
with ART (Bwirire, et al., 2008, Otieno, et al., 2010). Mothers are only offered ART according 
to guidelines and medication availability and do not recognize the necessity of follow up if they 
are not immediately eligible for ART. Only half of women referred for long-term treatment and 
care post PMTCT actually follow up (Otieno et al., 2010). 
2.6. Purpose of the study 
This study will examine the antenatal treatment regimens and mother-to-child 
transmission rates of HIV-infected mother and infant pairs receiving early infant diagnosis 
services at four government hospitals in Kenya.  
The study aims to: (1) describe antenatal treatment regimens documented for each mother 
to determine (a) the proportion of mothers who meet the 2010 World Health Organization 
(Options A and B) and Kenyan National AIDS and STI Control Programme Guidelines for the 
Prevention of Mother to Child Transmission (PMTCT) of HIV/AIDS in Kenya, (b) explore what 
PMTCT treatment regimens were followed at four hospital study sites, and (c) determine the 
trend in adherence to national and global guidelines from 2010 to 2012.  
Also the study aims to (2) assess if the infants born to mothers receiving no or 
insufficient PMTCT care were more likely to be diagnosed HIV positive.  
2.7. Study Hypotheses:  
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Hypothesis 1: More mothers will be treated in accordance with NASCOP guidelines than 
WHO guidelines at the four hospital sites because NASCOP guidelines are more lenient. Among 
hospital sites that adhere to WHO guidelines, more mothers will be treated in accordance with 
WHO Option A than Option B for the same reason as WHO Option A is more lenient than WHO 
Option B. 
Hypothesis 2:  There will be a trend towards improved adherence to both WHO and 
NASCOP guidelines from 2010 to 2012 as the guidelines are becoming widely disseminated. 
Hypothesis 3: Infants born to mothers who received no or insufficient PMTCT regimens 
will have higher rates of HIV-infection. 
Chapter 3 
Methodology 
3.1. Background 
Beginning in 2011, Global Health Innovations (GHI) and the Kenya Medical Research 
Institute (KEMRI) began piloting the HIV Infant Tracking System (HITSystem©) intervention 
in Pumwani Maternity Hospital in urban Nairobi, and shortly thereafter expanded to Mathare 
Hospital in Nairobi as well the Kapsabet and Kericho District Hospitals in the rural or peri-urban 
regions of western Kenya. A map depicting the hospital locations is presented in Figure 3 (Insert 
Figure 3 about here).  
A pre-post intervention evaluation design was employed to assess the impact of the 
HITSystem© on key EID outcomes. The HITSystem© is an online system that captures relevant 
data for the mother and infant at enrollment and subsequent visits, utilizing an algorithm 
programmed by the infant’s date of birth to generate automated action alerts when time-sensitive 
interventions for testing or treatment have been missed. Mothers’ PMTCT regimen, infant testing 
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information, and HIV status were among the additional variables collected through the 
HITSystem©.  
For the purposes of this study, a secondary analysis was conducted to determine if 
maternal and infant drug regimes were administered according to WHO and NASCOP 
guidelines. Dr. Sarah Finocchario-Kessler, Assistant Professor at the University of Kansas 
Medical Center and a collaborator with Global Health Innovations, provided the de-identified 
data for this thesis. The EID registries used prior to the HITSystem© indicated if the mother had 
PMTCT, but data regarding regimen and week of initiation were incomplete. Data collected 
through the HITSystem© intervention captured more comprehensive PMTCT-related data, and 
thus this analysis only utilized data collected through the HITSystem© (start date in April 2011). 
In addition an analysis was conducted to assess if infants born to mothers on less efficacious 
treatment regimes were more likely to test positive for HIV. 
3.2. Sample 
De-identified data for a total of 853 mother-infant pairs enrolled in early infant diagnosis 
(EID) were collected by clinical staff at each of the four hospitals using the HITSystem©. 
Pumwani Maternity Hospital and Mathare District Hospital are located in urban Nairobi. 
Kapsabet and Kericho District Hospitals are located in rural areas of western Kenya. All mothers 
presenting with their infants for EID follow-up were HIV+. Contextual information provided by 
clinical and research staff found that nearly all participants receiving care at these government 
hospitals are black Kenyans. Immigrants from neighboring African countries residing in Kenya 
may also be included in the patient population.  
3.3. Procedures 
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As per the existing protocol at each of the hospitals, data regarding mothers’ PMTCT 
history were collected both verbally from mothers at the time of enrolling their infant in EID 
care, and were cross referenced with the mother’s medical file.  
Maternal and infant data were collected through the HITSystem© for the duration of 
infant’s enrollment in EID care. Mothers’ were informed about the HITSystem© and given the 
opportunity to decline participation, in which their information was collected in the EID registry 
notebook (standard of care). No mothers opted to decline participation with the HITSystem©. 
Clinicians and staff at each facility were trained by Global Health Innovations staff on electronic 
reporting via the HITSystem© and informed consent procedures.  
The study protocol was approved by Institutional Review Board at the Kenya Medical 
Research Institute (KEMRI). Approval for this project was not sought through the University of 
Kansas Human Subjects in Research Committee. De-identified data were accessed from Global 
Health Innovations and analyzed for educational purposes only. The data analyses and written 
report are for the purposes of partial completion of a Master’s thesis, a required component of 
the Global and International Studies program at the University of Kansas. The findings of this 
study will not be used for generalization purposes and the student-researcher has no intention of 
publishing or disseminating the findings presented in this master’s thesis. 
3.4. Data cleaning and management 
 Data related to relevant variables were imported into excel files from the HITSystem© 
for each hospital, and were cleaned and coded in separate excel files before being merged into 
SPSS for analysis. Due to the nature of data collection there were instances where the mother’s 
medical file indicated that they received PMTCT prophylaxis, but the regimen was marked as 
“unknown” (N=15) or “other” (N=85) in the HITSystem©. As a result, these incomplete cases 
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were left out of the analyses when establishing whether a mother-infant pair meets the treatment 
guidelines as it is impossible to determine based on the available data. All statistical analyses 
were performed using IBM SPSS© version 20 for Windows. 
3.5. Variables 
To address hypothesis 1, regarding the percentage of mothers treated in accordance with 
NASCOP and WHO guidelines, PMTCT drug regimens and week of PMTCT treatment 
initiation were examined for each mother included in the sample. Drawing from the study model 
of Azcoaga-Lorenzo and colleagues (2011) regimens were coded into four categories: (1) meets 
guidelines (ARV prescribed in perfect agreement with guidelines), (2) late treatment initiation 
(correct ARVs prescribed later than guidelines recommends), (3) insufficient treatment (incorrect 
ARV regimen), or (4) no intervention (no ARV prescribed). As stated above, cases where 
mothers’ PMTCT regimen could not be determined were left out of the analysis. The grouping 
variable categorizing mother-infant pairs by hospital served as the independent variable and the 
variables examining whether or not each mother received PMTCT according to the guidelines 
was the dependent variable.  
Three new variables were created to indicate if the mother was treated in compliance with 
NASCOP, WHO Option A, and WHO Option B guidelines. If mothers were treated with AZT, 
dual AZT therapy, or HAART and treatment initiation was 28 weeks or sooner they were coded 
as ‘1’ for meeting NASCOP guidelines. If mothers were treated with AZT, dual AZT therapy, or 
HAART and treatment initiation was 14 weeks or sooner they were coded as ‘1’ for meeting 
WHO Option A guidelines. If mothers were on HAART therapy they were coded as ‘1’ for 
meeting WHO Option B guidelines.  
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Hypothesis 2 addresses week of treatment initiation to assess if there has been a trend 
towards earlier treatment initiation from 2010 until 2012.  Mother-infant pairs were coded into 
categories based on their date of birth and an assumed 40 week gestation period. Given that 
WHO recommends PMTCT beginning shortly after the second trimester, infants were coded 
based on the year in which the majority of the final two-thirds of gestation occurred (i.e. 1=2010, 
2=2011, and 3=2012). The grouping variable examining year of pregnancy served as the 
independent variable and week of treatment initiation was the dependent variable. 
PMTCT regimens and infant HIV status were examined to address hypothesis 3. Infants 
were coded as ‘0’ if HIV-negative, ‘1’ if HIV-positive, and ‘2’ if HIV test results were 
indeterminate. Mothers were coded as ‘1’ if they were on PMTCT that included AZT alone or 
dual AZT therapy, ‘2’ if they were HAART, and ‘3’ if they were on NVP. Mothers that were on 
regimens marked as “unknown” or “other” were left out of this analysis. Infant HIV status was 
the dependent variable in this analysis and mother’s PMTCT treatment regimen was the 
independent variable. 
3.6. Analyses 
To describe the quality of PMTCT services at the four study hospitals, various statistical 
analyses were conducted. Frequencies and percentages were calculated for categorical variables 
such as whether mothers received PMTCT therapy, PMTCT regimens, and infant HIV status. 
Measures of central tendency and variability (mean, median, range, and standard deviation) were 
examined for continuous variables such as week of PMTCT treatment initiation.  
To address hypothesis 1 and determine if WHO and NASCOP-specific PMTCT 
guidelines were met, two criteria were evaluated: regimen and week of treatment initiation. To 
address the second hypothesis, ANOVA was used to compare week of treatment initiation 
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between mothers receiving PMTCT in 2010, 2011 and 2012. To answer hypothesis 3, 
frequencies and percentages were examined to determine if infant’s HIV status was associated 
with the absence of PMTCT care of the mother.  
CHAPTER 4 
Results 
4.1. Describing PMTCT care among HIV+ women 
 Among the 853 mother-infant pairs, 85.11% (n=726) received some form of antiretroviral 
therapy for the prevention of mother-to-child HIV transmission. Average week of PMTCT 
treatment initiation among mothers was 24.02 weeks with a median and mode of 28 weeks, and 
standard deviation of 9.80 weeks. Week of treatment initiation at individual hospitals will be 
described in greater detail in section 4.2. 
 Pumwani Maternity Hospital experienced the highest percentage of women receiving 
PMTCT with 97.63% of mothers receiving treatment. Mathare District Hospital, similar to 
Pumwani, also had a high proportion of mothers on PMTCT with 90.32% of mothers receiving 
treatment. Kapsabet and Kericho District Hospitals had the lowest percentages of mothers 
receiving PMTCT with 64.23% and 56.69% respectively.  
 As stated earlier, PMTCT regimen information was marked as “other” in 85 cases and 
“unknown” in 15 cases. As a consequence, only 86.23% (n= 626 out of the 726 mothers who 
received PMTCT) mother-infant pairs were analyzed for PMTCT regimen-specific data. Of the 
626 mothers where PMTCT regimen is documented the most common regimen among all four 
hospitals was AZT alone or in combination with either NVP or 3TC (n=598, 95.5%). HAART 
was the second most common regimen (n=23, 3.7%), and 5 (0.01%) mothers reported being 
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treated with nevirapine only. Table 1 depicts a breakdown of the sample and overall findings by 
hospital (Insert Table 1 about here).  
4.2. Meeting national and global PMTCT guidelines 
Table 2 shows the proportion of mothers that received PMTCT in accordance with each 
of the treatment guidelines (i.e. NASCOP, WHO Option A, and WHO Option B). Table 3 shows 
the same proportions, but also includes a breakdown of mothers that were treated with 
insufficient regimens, receiving late treatment initiation, or no treatment intervention. The 
majority of mothers were treated in accordance with NASCOP guidelines (n=577, 76.6%) which 
in this case meant they were treated with an ARV regime that included AZT or HAART 
commencing at 28 weeks gestation. WHO Option A requires AZT or HAART commencing at 14 
weeks gestation. Only 63 (8.4%) mothers met the treatment requirements for WHO Option A. 
Requirements for WHO Option B recommend HAART commencing at 14 weeks gestation. Only 
13 (1.5%) mothers met the recommendations for WHO Option B. Hypothesis 1 was validated as 
the majority of mothers were treated under the NASCOP guidelines followed by WHO Option A 
and then WHO Option B. 
In total 44 (5.8%) mothers received late treatment initiation according to NASCOP 
guidelines (i.e. treatment initiation later than 28 weeks gestation). This number increased 
substantially when looking at WHO Option A with 558 (74.1%) of mothers receiving late 
treatment initiation under Option A. Of the 23 mothers receiving the triple antiretroviral therapy 
or HAART regime required under WHO Option B, 10 (1.3%) received late treatment initiation 
according to WHO Option B.  
Pumwani had the highest overall proportion of mothers treated in accordance with 
NASCOP guidelines as 96.7% (n = 436) were treated. Mathare had the second highest with 
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72.4% (n = 63), followed by Kapsabet with 41.8% (n = 46), and Kericho with 30.5% (n = 32). 
When looking at WHO Option A, Mathare had the highest overall proportion of mothers treated 
in accordance with guidelines with 39.1% (n = 34) of mothers treated according to Option A. 
Kericho had the second highest proportion treated in accordance with Option A at 13.3% (n = 
14), followed by Kapsabet with 11.8% (n = 13), and Pumwani with 0.4% (n = 2). All 13 of the 
infants treated in proper accordance with WHO Option B were at the Kapsabet District Hospital.  
4.3. Trends in PMTCT care 
A one-way ANOVA (Insert Table 4 about here) was conducted to determine if earlier 
PMTCT treatment initiation was observed from the time updated treatment guidelines were 
released in 2010 until 2012. Mean week of treatment initiation was calculated for each year and 
are presented in Table 4 as well as Figure 4 (Insert Table 4 and Figure 4 about here). There was a 
significant change or improvement in week of PMTCT treatment initiation observed at the p<.05 
level over the three years [F(2, 723) = 13.725, p = 0.000]. Post hoc comparisons using the Tukey 
HSD test (Insert Table 5 about here) indicated that the mean week of treatment initiation in 2010 
(M = 27.11, SD = 5.24) was significantly different than both 2011 (M = 23.19, SD = 10.61) and 
2012 (M = 20.26, SD = 11.77). There was no significant difference between week of treatment 
initiation in 2011 and 2012. However, it is important to broach the 2012 findings with caution as 
there as a low number of mother-infant pairs in the 2012 category (N = 34) compared with 2010 
(N = 180) and 2011 (N = 512). Standard deviation and standard error was high in the 2012 
category (SD = 11.77 and SE = 2.019). Nevertheless, the significant difference between 2010 
and 2011 suggest that Kenya is moving towards greater adherence to WHO Option A guidelines 
and also validates hypothesis 2.  
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 Mean week of treatment initiation varied between hospitals (Insert Figure 5 about here). 
Mathare had the earliest mean week of treatment initiation at 14.08 weeks gestation followed by 
Kapsabet with 16.68, Kericho with 24.00 weeks, and Pumwani with 27.90 weeks.  
4.4. HIV transmission among infants 
Among the infants participating in EID care, 95.55% (n=815) were tested for HIV. 
Among the 815 infants that were tested for HIV, forty-one infants were found to be HIV positive 
and 3 had indeterminate HIV results. Overall HIV prevalence among infants tested in the sample 
was 5.03%. HIV prevalence varied between hospitals. Pumwani Maternity Hospital had the 
lowest infant HIV prevalence at 2.37% followed by Kericho District Hospital with 2.75%. 
Kapsabet and Mathare District Hospitals had the highest infant HIV prevalence in this sample. 
At Kapsabet 8.96% of infants were HIV-infected and at Mathare HIV prevalence was the highest 
of the four hospitals at 13.89%. Of the 41 positive infants, mother’s PMTCT status and regimen 
was known for 35 of the positive infants. The remaining 6 were mothers on PMTCT regimens 
marked as “unknown” or “other.” 
Hypothesis 3 was validated in examining treatment regimens. Of the 35 HIV+ infants 
where mother’s PMTCT regimen was known, 16 received no PMTCT intervention comprising 
14.03% of the total sample of untreated mothers. Nineteen of the HIV+ infants had mothers who 
received a single or dual combination AZT regimen comprising 2.72% of total sample of 
mothers receiving PMTCT. None of the infants receiving triple antiretroviral therapy or 
nevirapine-only regimens tested positive for HIV. As stated earlier, 6 of the infants who tested 
HIV+ had mothers who were on PMTCT regimens marked as “unknown” or “other.” 
CHAPTER 5 
Discussion 
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5.1. Strengths and limitations 
 Reported uptake in PMTCT therapy was high among this sample with 85.11% of mothers 
receiving PMTCT. Kenya’s National AIDS Control Council (2011) reported that 69.2% of 
women received PMTCT in 2011. One of the best successes to report in in this sample was the 
minimal use of single-dose nevirapine as PMTCT therapy. Only 5 (0.01%) women on PMTCT 
prophylaxis in this sample were treated with single-dose nevirapine compared to the 2011 
Kenyan national average of 4.2% (NACC, 2011). Both the national average and the average 
found amongst the sample in this study are a success for the rapid dissemination and 
implementation of the NASCOP and WHO guidelines. 
Future research is planned to examine the success of the HITSystem© intervention 
focusing on EID indicators both pre and post HITSystem©. HIV prevalence among infants in 
this sample was similar to national averages at 5.03%. However, prevalence varied between 
hospitals and Mathare District Hospital experienced a much higher infant HIV prevalence at 
13.89% than the other hospitals. This is troublesome given the fact that uptake in PMTCT was 
high with 90.32% of women at Mathare receiving PMTCT therapy. In addition, Mathare also 
had the earliest week of treatment initiation at 14.08 weeks and the highest proportion of mothers 
treated in accordance with WHO Option A as opposed to the less stringent NASCOP guidelines. 
Given this information, one would expect Mathare to have the lowest proportion of HIV+ 
infants. However, the Mathare district is one of Kenya’s largest slums (Karanja and Makau, 
2010) and quality of life and health indicators could also be impacted by larger biological and 
socioeconomic factors. Further exploration into Mathare’s outcomes may be necessary and could 
be identified if additional social and economic demographic variables were collected in the 
future. 
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Pumwani had the best outcomes overall with the highest percentage of mothers treated in 
accordance to NASCOP guidelines and the lowest percentage of HIV+ infants. This could be due 
in part to the specialized nature of Pumwani as the only hospital in the sample focusing strictly 
on maternal and child health. By incorporating PMTCT and EID care into the normal flow of 
maternal health services perhaps Pumwani is able to better manage and follow up with patients. 
Pumwani’s positive outcomes could be attributed to their integration of PMTCT services into 
their antenatal care program which was discussed as a potential barrier earlier in this thesis 
(Azcoaga-Lorenzo et al., 2011, Otieno, et al., 2010). Based on their strict adherence to the 
NASCOP guidelines and high uptake in both PMTCT and EID services it would be worth taking 
a closer look at their services and clinic flow to determine if it would be an appropriate model for 
other clinics in Kenya. 
There are several additional limitations in this study. Data regarding mother’s PMTCT 
regimen were limited in 100 cases and variables in some cases were missing entirely. The reality 
of collecting global health data in the field warrants discussion as it is important to point out that 
data were collected from currently-operating EID programs. The HITSystem© is a resource 
designed for utilization in a clinical setting and is dependent upon self-reported PMTCT history 
as well as human data entry and chart review. As a result, missing information regarding 
PMTCT regimens were regarded as untreated when in reality the information may not have been 
available or obtained. The high number of PMTCT regimens entered at “other” or “unknown” (n 
= 100) was also problematic in this sample. These individuals had to be left out of analyses 
examining PMTCT regimens and 6 of the 41 infants that were HIV+ had mothers on PMTCT 
regimens marked as “other” or “unknown.” It would be particularly helpful to obtain the 
mother’s PMTCT regimen in cases where the infant had an indeterminate or HIV-positive test 
34 
 
result. The 100 “missing” or “unknown” regimen cases were dispersed evenly across all of the 
hospitals so perhaps follow up with each site to determine why regimens were entered into the 
HITSystem© this way would be advantageous. 
Second, additional variables such as mother’s age, education level, socioeconomic status, 
or substance use could more thoroughly explain the outcome of these findings, but were not 
collected. Moreover, the data included self-reported PMTCT regimen history; however there was 
no variable that could be used to measure or predict adherence to antiretroviral therapy. 
Consequently, it cannot be determined if PMTCT medications were taken consistently, correctly, 
or at all. Previous research (Azcoaga-Lorenzo et al., 2011, Delva et al., 2010, Hassan et al., 2012, 
Otieno et al., 2010) has demonstrated that demographic characteristics such as mother’s age, 
education level, socioeconomic status, or substance use can also influence adherence so in the 
future it would be helpful to have comprehensive demographic information about mothers. 
Further, previous research has demonstrated that mothers who deliver at home also report lower 
adherence to PMTCT therapy (Azcoaga-Lorenzo et al., 2011, NACC, 2011). Such mothers need 
to be brought into mainstream care to prevent mother-to-child transmission of HIV. 
 Third, governmental and societal factors could have also impacted the results of this 
study. Overall findings of this study with low nevirapine use, high percentages of mothers 
receiving PMTCT, and a movement towards earlier week of treatment initiation indicate a rapid 
uptake in the new NASCOP and WHO guidelines. Despite the fact that there are guidelines in 
place it can often take several years to disseminate guidelines for full implementation by 
providers and some bottlenecks or treatment gaps will continue to persist. With the HITSystem© 
intervention in place it will be possible to examine regimen data again in the future and include a 
more exhaustive sample over a longer period of time. Furthermore, it will be valuable to examine 
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future regimen data to see if greater movement is seen towards adherence to Options B/B+ as the 
Kenyan government is committed to establishing Options B/B+ as the standard of PMTCT care 
in upcoming years (Médecins Sans Frontières/Doctors Without Borders, 2012, Bachman and 
Phelps, 2012).  
 Fourth, one major clinical outcome missing from this sample was the mother’s CD4 and 
viral load during pregnancy. Collecting the mother’s clinical measures for CD4 and viral load 
may also be a helpful indicator as women with lower CD4 and higher viral load are more likely 
to transmit HIV infection to their infants (Cole et al., 1997, Rousseau et al., 2003). This 
information could be useful in explaining the cases where infants tested positive in spite of 
having mothers on adequate treatment. 
5.2. Implications for research, policy, and practice 
 Both NASCOP and WHO Option A recommend AZT during the antenatal period for 
PMTCT. The key difference between the guidelines for NASCOP and WHO Option A is week 
of treatment initiation. NASCOP guidelines recommend commencing treatment at 28 weeks 
gestation or as soon as possible thereafter, whereas WHO Option A recommends 14 weeks. 
From 2010 to 2012 a positive and statistically significant trend towards earlier treatment 
initiation was observed. As noted earlier in the discussion, very few mothers in this sample were 
treated with single-dose nevirapine for PMTCT. Both findings are likely due to the fact that the 
PMTCT guidelines are being talked about and disseminated throughout Kenya. If this trend 
continues, it is probable that an increase in individuals treated in accordance with WHO Option 
A will be observed. However, the Kenyan government is now committed to scaling up treatment 
to Option B/B+ which will be notably more difficult given the low percentage (1.7%) of infants 
in this study that were treated in accordance with WHO Option B. 
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In addition, antiretroviral treatment in the developing world is often dependent on 
external factors such as funding from global health organizations or NGOs that should be taken 
into consideration. Kenya’s HIV/AIDS program has a budget of 629 million dollars with 510 
million of that budget coming from the United States PEPFAR program, 34 million from the 
government of Kenya, and an additional 32.5 million coming from the Global Fund to Fight 
AIDS, Tuberculosis, and Malaria (NACC, 2011). With Kenya’s population growing at a more 
rapid pace than other sub-Saharan African countries (World Bank, 2010), Kenya will need to at 
minimum maintain and perhaps increase this funding to fully scale up treatment options in the 
future (NACC, 2011). 
 Another factor that will be worth examining in the future is the disparities between the 
urban and peri-urban or more rural clinical locations. According to World Bank (2010) 
estimates, 78% of Kenyans reside in rural areas. In this study, women at the Pumwani and 
Mathare hospitals in urban Nairobi received PMTCT at higher percentages than at the peri-urban 
locations of Kapsabet and Kericho in western Kenya. Women in the peri-urban locations may be 
traveling to receive clinical care from far-reaching rural areas. Transportation has been cited in 
several studies (Bwirire et al, 2008, Delva et al., 2010, Hassan et al., 2012, Otieno et al., 2010) as 
a barrier to engaging in PMTCT or EID care. Women in rural areas, in particular, report 
struggling with transportation issues as a result of having to travel to a more central or urbanized 
setting.  Collecting information regarding distance travelled to clinical appointments may be 
advantageous in the future to determine if there is a considerable difference between the urban 
and rural mothers in this sample. Additionally it may be worthwhile to examine access to 
treatment among the particular urban and peri-urban clinics to determine if the peri-urban or 
rural locations have more difficulty in accessing antiretroviral therapy. Drug shortages have been 
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identified as a deterrent to treatment in the past and individuals have reported being unable to 
obtain prescribed regimens (NACC, 2011). 
 An analysis examining the lost to follow-up infants would be relevant in the future as 
some of the infants enrolled in EID care were not tested for HIV and did not engage in follow-
up. Future research with the HITSystem© plans to address this issue as information regarding 
lost to follow-up infants has been collected since the onset of this study. 
5.3) Conclusion 
 With the introduction of updated guidelines for PMTCT in 2010, the World Health 
Organization provided developing countries with streamlined options for establishing a new 
standard of care for PMTCT. By adapting the guidelines, countries like Kenya have the ability to 
more effectively hone in on their own resource bases to determine possible treatment outcomes. 
In assessing WHO and NASCOP guidelines, this study determined that the majority of the 853 
mother-infant pairs in this sample are being treated in accordance with the Kenya-specific 
NASCOP guidelines. However, significant work needs to be done to improve uptake of Options 
A and B/B+. While it is likely that some clinical, patient and societal barriers exist, results of this 
study indicate a significant trend towards early initiation of PMTCT treatment among the 
hospitals in this study.  
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Figure 1: WHO clinical staging of HIV disease in adults and adolescents 
Clinical stage 1 
 Asymptomatic 
 Persistent generalized lymphadenopathy 
Clinical stage 2 
 Moderate unexplained weight loss (under 10% of presumed or measured body weight) 
 Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media, pharyngitis) 
 Herpes zoster 
 Angular cheilitis 
 Recurrent oral ulcerations 
 Papular pruritic eruptions 
 Seborrhoeic dermatitis 
 Fungal nail infections 
Clinical stage 3 
 Unexplained severe weight loss (over 10% of presumed or measured body weight) 
 Unexplained chronic diarrhea for longer than 1 month 
 Unexplained persistent fever (intermittent or constant for longer than 1 month) 
 Persistent oral candidiasis 
 Oral hairy leukoplakia 
 Pulmonary tuberculosis 
 Severe bacterial infections (e.g. pneumonia, empyema, meningitis, pyomyositis, bone 
or joint infection, bacteraemia, severe pelvic inflammatory disease) 
 Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
 Unexplained anaemia (below 8 g/dl ), neutropenia (below 0.5 x 109/l) and/or chronic 
thrombocytopenia (below 50 x 109/l) 
Clinical stage 4 
 HIV wasting syndrome 
 Pneumocystis jiroveci pneumonia 
 Recurrent severe bacterial pneumonia 
 Chronic herpes simplex infection (orolabial, genital or anorectal of more than 1 month’s 
duration or visceral at any site) 
 Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) 
 Extrapulmonary tuberculosis 
 Kaposi sarcoma 
 Cytomegalovirus disease (retinitis or infection of other organs, excluding liver, spleen 
and lymph nodes) 
 Central nervous system toxoplasmosis 
 HIV encephalopathy 
 Extrapulmonary cryptococcosis including meningitis 
 Disseminated nontuberculous mycobacteria infection 
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 Progressive multifocal leukoencephalopathy 
 Chronic cryptosporidiosis 
 Chronic isosporiasis 
 Disseminated mycosis (histoplasmosis, coccidiomycosis) 
 Recurrent septicaemia (including nontyphoidal Salmonella) 
 Lymphoma (cerebral or B cell non-Hodgkin) 
 Invasive cervical carcinoma 
 Atypical disseminated leishmaniasis 
 Symptomatic HIV-associated nephropathy or HIV-associated cardiomyopathy 
Note. From “Antiretroviral drugs for treating pregnant women and preventing HIV infection in 
infants.” World Health Organization, 2010, p. 27-28.  
 
 
51 
 
Figure 2: WHO and NASCOP 2010 guidelines for PMTCT  
 WHO 2010 Guidelines NASCOP 2010 Guidelines 
Prophylaxis  
(Women with CD4 count >350 
cells/mm3) 
Prophylaxis  
(Women with CD4 count >350  
cells/mm3) 
Option A  Antepartum: AZT starting as early as 
14 weeks gestation. 
Intrapartum: at onset of labor, sdNVP 
and first dose of AZT/3TC. 
Postpartum: daily AZT/3TC through 7 
days postpartum.  
Antepartum: AZT starting as early as 
28 weeks gestation. 
Intrapartum: at onset of labor, 
sdNVP and first dose of AZT/3TC. 
Postpartum: daily AZT/3TC through 7 
days postpartum. 
Option B  Triple ARVs starting as early as 14 
weeks gestation and continued 
intrapartum and through childbirth if 
not breastfeeding or until 1 week after 
cessation of all breastfeeding.  
 
Option B+  Regardless of CD4 count, triple ARVs 
starting as soon as diagnosed, continued 
for life. 
 
 
Note. Adapted from “Programmatic update: Use of antiretroviral drugs for treating pregnant women and 
preventing HIV infection in infants.” World Health Organization, 2012, p. 2. and “Guidelines for 
prevention of mother to child transmission of HIV/AIDS in Kenya.” Kenya Ministry of Health, National 
AIDS and STI Control Programme, 2010, p. 46-47.  
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Figure 3: Map of Kenya with study hospitals 
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Figure 4: Mean week of PMTCT treatment initiation by year (2010-2012) 
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Figure 5: Mean week of PMTCT treatment initiation by hospital 
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Table 1: Description of sample by hospital 
 
Hospital 
 
Kapsabet Kericho Mathare Pumwani Total 
Total sample of 
mother-infant 
pairs 
137 (16.06%) 127 (14.89%) 124 (14.54%) 465 (54.51%) 853 (100%) 
Mother on 
PMTCT 
88 (64.23%) 72 (56.69%) 112 (90.32%) 454 (97.63%) 726 (85.11%) 
Infants tested 
for HIV 
134 (97.81%) 109 (85.83%) 108 (87.10%) 464 (99.78%) 815 (95.55%) 
Infants testing 
HIV+ 
12 (8.96%) 3 (2.75%) 15 (13.89%) 11 (2.37%) 41 (5.03%) 
Infants with an 
indeterminate 
HIV test result 
1 (0.75%) 1 (0.92%) 1 (0.93%) 0 (0%) 3 (0.37%) 
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Table 2: Description of hospitals meeting NASCOP, WHO Option A, and WHO Option B 
PMTCT guidelines 
 
 
 
 
 
Hospital  
N = total 
minus 
missing 
Number (%)* 
meeting NASCOP 
2010 Guidelines 
Number (%)* meeting 
WHO  
2010 Guidelines 
Option A 
Number (%)* 
meeting WHO 
2010 Guidelines 
Option B 
Missing or  
Unknown Regimen 
(n = 100/853) 
Kapsabet 
n = 110  
46 (41.8%) 13 (11.8%) 13 (11.8%) 27 (19.7 %) 
Kericho 
n = 105 
32 (30.5%) 14 (13.3%) 0 0%) 22 (17.3%) 
Mathare  
n = 87 
63 (72.4%) 34 (39.1%) 0 (0%) 37 (29.8%) 
Pumwani 
n = 451 
436 (96.7%) 2 (0.4%) 0 (0%) 14 (3.0%) 
Total  
N = 753 
577 (76.6%) 63 (8.4%) 13 (1.7%) 100 (11.7%) 
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Table 3: Breakdown of adherence to NASCOP, WHO Option A, and WHO Option B PMTCT 
guidelines by hospital 
 
*Note. Total indicates percentage minus n=100 cases with unknown or missing regimen information. 
**Note. Individuals receiving no intervention are the same across all three guidelines. 
 
Hospital  Guideline Meets 
guidelines  
Late treatment 
initiation 
Insufficient 
regimen 
No intervention 
Kapsabet 
n = 110 
NASCOP 46 (41.8%) 15 (13.6%) 0 (0%) 
49 (44.5%)** WHO Option A 13 (11.8%) 48 (43.6%) 0 (0%) 
WHO Option B 13 (11.8%) 0 (0%) 48 (43.6%) 
Kericho 
n = 105 
NASCOP 32 (30.5%) 14 (13.3%) 4 (3.8%) 
55 (52.4%)** WHO Option A 14 (13.3%) 32 (30.5%) 4 (3.8%) 
WHO Option B 0 (0%) 0 (0%) 50 (47.6%) 
Mathare  
n = 87 
NASCOP 63 (72.4%) 11 (12.6%) 1 (1.1%) 
12 (13.8%)** WHO Option A 34 (39.1%) 40 (46.0%) 1 (1.1%) 
WHO Option B 0 (0%) 0 (0%) 75 (86.2%) 
Pumwani 
n = 451 
NASCOP 436 (96.7%) 4 (0.9%) 0 (0%) 
11 (2.4%)** WHO Option A 2 (0.4%) 438 (97.1%) 0 (0%) 
WHO Option B 0 (0%) 10 (2.2%) 95.3% 
Total  
N =753* 
NASCOP 577 (76.6%) 44 (5.8%) 5 (0.7%) 
127 (16.9%)** WHO Option A 63 (8.4%) 558 (74.1%) 5 (0.7%) 
WHO Option B 13 (1.5%) 10 (1.3%) 603 (80.1%) 
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Table 4: One-way ANOVA for mean week of treatment initiation by year 2010-2012 
 
Year 
N Mean Standard 
Deviation 
Standard Error 
95% CI 
Lower  
Bound 
Upper  
Bound 
2010  180 27.11 5.24 .391 26.33 27.88 
2011 512 23.19 10.61 .469 22.27 24.11 
2012 34 20.26 11.77 2.019 16.16 24.37 
Total 726 24.02 9.80 .364 23.31 24.74 
 SS df F p 
Between Groups 2546.367 2 13.725 .000 
Within Groups 67066.235 723   
Total  
 
69612.602 725   
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Table 5: Post-hoc analyses of ANOVA with Tukey HSD  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Note. The mean difference is significant at the 0.05 level. 
 
Year 
Pregnancy 
Year 
Pregnancy 
Mean 
Difference 
p 
95% CI 
Lower  
Bound 
Upper  
Bound 
2010  
2011 
2012 
3.916* 
6.841* 
.000 
.000 
1.96 
2.61 
5.88 
11.07 
2011 
2010 
2012 
-3.916* 
2.925 
.000 
.200 
-5.88 
-1.08 
-1.96 
6.93 
2012 
2010 
2011 
-6.841* 
-2.925 
.000 
.200 
-11.07 
-6.93 
-2.61 
1.08 
